The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.

Among the various aspects of the present disclosure is the provision of compositions of NRF2 inhibiting agents and methods of use thereof. These agents can be useful for cancer treatment, including as radiosensitizing agents and as chemotherapeutic sensitizing agents.

Among the various aspects of the present disclosure is the provision of compositions of NRF2 inhibiting agents and methods of use thereof. These agents can be useful for cancer treatment, including as radiosensitizing agents and as chemotherapeutic sensitizing agents.

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: ##STR00001##
wherein the variable groups X, R.sup.1, R.sup.2, R.sup.3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: ##STR00001##
wherein the variable groups X, R.sup.1, R.sup.2, R.sup.3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.

The present invention provides a compound of the formula (2): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.8, Y.sup.1, Y.sup.2, and L are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

The present invention provides a compound of the formula (2): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.8, Y.sup.1, Y.sup.2, and L are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

The disclosure includes non-naturally occurring or engineered DNA- or RNA-guided nuclease systems, comprising CRISPR enzymes associated with at least one destabilization domain (DD) and photocaged stabilization ligands with at least one photocage molecule, along with compositions, systems and complexes involving such systems, nucleic acid molecules and vectors encoding the same, delivery systems involving the same, uses thereof.

The disclosure includes non-naturally occurring or engineered DNA- or RNA-guided nuclease systems, comprising CRISPR enzymes associated with at least one destabilization domain (DD) and photocaged stabilization ligands with at least one photocage molecule, along with compositions, systems and complexes involving such systems, nucleic acid molecules and vectors encoding the same, delivery systems involving the same, uses thereof.

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.